Procter & Gamble Health — 360° view

Procter & Gamble Health, a company in the Pharmaceuticals industry, reported revenue of ₹382 crore and net profit of ₹112 crore for the September 2026 quarter.

Procter & Gamble Health (NSE: PGHL) closed at ₹5,589.50 on 20 Nov 2026, down 2.5% over the past year. Its market capitalisation is ₹9,278 crore and it trades at 26.1 times earnings.

Share price
₹5,589.50 (20 Nov 2026)
Market cap
₹9,278 Cr (20 Nov 2026)
P/E
26.05 (20 Nov 2026)
Revenue
₹382 Cr (September 2026 quarter)
Net profit
₹112 Cr (September 2026 quarter)
ROCE
83.9% (FY26)
ROE
61.9% (FY26)
Book value
₹396 (FY26)
Dividend yield
4.47% (last 12 months to 20 Nov 2026)
52-week high / low
₹6,975.00 / ₹4,707.00 (20 Nov 2026)
1-year return
-2.5% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: PGHL

Procter & Gamble Health Ltd, formerly Merck Ltd, manufactures and markets vitamins, minerals, supplements and other healthcare products under brands including Neurobion, Livogen, Seven Seas, Evion, Polybion and Nasivion. It is part of the US-based P&G Group and operates a plant at Usgaon, Goa

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.